Aspire Biopharma (ASBP) announced initiation of its Phase 1 single- center clinical study of its lead therapeutic candidate, an oral ...

Aspirin was also shown to have an additional benefit in patients given a thrombolytic agent. (Source: https://pubmed.ncbi.nlm.nih.gov/2903874/) Greater bioavailability of ASA, through the oral ...

an oral transmucosal fast-acting high-dose aspirin formulation. One clinical trial site has been activated with patient enrollment expected to total six to eight participants and begin during April.

Aspire Biopharma Holdings, Inc, a developer of a multi-faceted patent-pending drug delivery technology, announced initiation of its phase 1 single-centre clinical study of its lead therapeutic ...

An oral transmucosal acetylsalicylic acid (OTASA) product associated with rapid absorption and antiplatelet effects could provide important benefits for patients experiencing acute myocardial ...

One clinical trial site activatedPatient enrollment expected in AprilTrial designed to evaluate safety, pharmacokinetics and pharmacodynamics, of Aspire's sublingual aspirin productAspire anticipates ...